Printer Friendly

Halozyme Therapeutics Presents rHuPH20 Hyaluronidase Preclinical Data at the 2005 American Association for Cancer Research; - rHuPH20 Enzyme Increases Tumor Sensitivity to Chemotherapy -.

ANAHEIM, Calif. and SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a development stage biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, announced today that results from new preclinical studies investigating the use of Halozyme's recombinant human PH20 (rHuPH20) hyaluronidase enzyme in conjunction with chemotherapy were presented today at the American Association for Cancer Research Annual Meeting in Anaheim, California. Studies conducted in collaboration with the University of Trondheim, Norway, showed that rHuPH20 reduced both tumor interstitial fluid pressure in animal models and the resistance of cultured human bladder carcinoma aggregates to a commonly used chemotherapy agent.

Bladder carcinoma cells were found to become more resistant to chemotherapy when they were grown as multicellular aggregates shaped as spheres (i.e., "spheroids") vs. grown as flat single cell layers, potentially due to the gel-like substance made of hyaluronic acid (HA) that surrounds the spheroids and acts as a barrier to the dispersion and penetration of chemotherapy into tumors. After the addition of rHuPH20 to the tumor aggregates to remove the HA, investigators demonstrated increased penetration of chemotherapeutic agents and greater cell killing in the treated spheroids vs. controls. The chemosensitivity of the tumor cells increased to the point where they exhibited the same degree of chemosensitivity as the flat single cell layers, which can be potentially attributed to the increased accessibility of tumor cells by chemotherapy once the HA barrier was removed.

"The challenge for chemotherapy to effectively reach the inner core of tumors is often forgotten when studying cells grown in petri dishes," said Gregory Frost, PhD, Halozyme's Vice President and Chief Scientific Officer. "These studies lay the pharmacologic foundation for the development of Chemophase(TM), and generally support the previous positive clinical findings from treating transitional bladder cancer patients with animal-sourced hyaluronidase and chemotherapy. We are excited about pursuing the development of a potential new bladder cancer treatment, which we plan to bring into the clinic in the second half of this year, pending appropriate FDA authorization."

Halozyme's rHuPH20 is a highly purified, recombinant form of the naturally occurring human enzyme and is being investigated for its ability to break down hyaluronic acid (HA), the space-filling "gel"-like substance that is a major component of tissues throughout the body. Hyaluronidase injected in the bladder through intravesical administration may temporarily digest the HA gel found around bladder tumor cells to potentially enhance the penetration and diffusion of other administered drugs, such as chemotherapy.

About Halozyme Therapeutics, Inc.

Halozyme is a development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's portfolio of products under development is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived enzymes that carry potential risks of animal pathogen transmission and immunogenicity. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic biologic.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning research data, products under development and the timing of expected clinical development) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-KSB, 10-QSB and other filings with the Securities and Exchange Commission.
 Halozyme Contact Investor Relations Contacts
 David A. Ramsay Ina McGuinness / Bruce Voss
 Chief Financial Officer Lippert/Heilshorn & Associates
 (858) 794-8889 (310) 691-7100

 Media Contacts
 Kathy Sweeney / Joleen Schultz
 858-455-5500, x230/x215

CONTACT: David A. Ramsay, Chief Financial Officer of Halozyme Therapeutics, Inc., +1-858-794-8889,; or Investor Relations, Ina McGuinness,, or Bruce Voss, both of Lippert/Heilshorn & Associates, +1-310-691-7100, for Halozyme Therapeutics, Inc.; or Media, Kathy Sweeney, ext. 230,, or Joleen Schultz, ext. 215,, both of Mentus, +1-858-455-5500, for Halozyme Therapeutics, Inc.
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 19, 2005
Previous Article:Network Installation Awarded $128,000 in New Wireless & Networking Projects.
Next Article:RoseStreet Labs Announces Full Spectrum Solar Cell Commercialization Agreement With Cornell University.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters